Participants 58 83 6
myelodysplastic disorders
Participants 229 274 7
patients with myelodysplastic syndromes (MDS)
Participants 276 315 8
Sixty-eight evaluable patients with MDS
Participants 952 960 3
patients
Participants 964 975 3
both groups
Participants 1293 1310 4
patients with MDS
